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Abstract
Dramatic advances in recent decades in understanding the genetics of Friedreich ataxia (FRDA)—a GAA triplet expansion
causing greatly reduced expression of the mitochondrial protein frataxin—have thus far yielded no therapeutic dividend,
since there remain no effective treatments that prevent or even slow the inevitable progressive disability in affected
individuals. Clinical interventions that restore frataxin expression are attractive therapeutic approaches, as, in theory, it may
be possible to re-establish normal function in frataxin deficient cells if frataxin levels are increased above a specific
threshold. With this in mind several drugs and cytokines have been tested for their ability to increase frataxin levels. Cell
transplantation strategies may provide an alternative approach to this therapeutic aim, and may also offer more widespread
cellular protective roles in FRDA. Here we show a direct link between frataxin expression in fibroblasts derived from FRDA
patients with both decreased expression of hydrogen peroxide scavenging enzymes and increased sensitivity to hydrogen
peroxide-mediated toxicity. We demonstrate that normal human mesenchymal stem cells (MSCs) induce both an increase in
frataxin gene and protein expression in FRDA fibroblasts via secretion of soluble factors. Finally, we show that exposure to
factors produced by human MSCs increases resistance to hydrogen peroxide-mediated toxicity in FRDA fibroblasts through,
at least in part, restoring the expression of the hydrogen peroxide scavenging enzymes catalase and glutathione peroxidase
1. These findings suggest, for the first time, that stem cells may increase frataxin levels in FRDA and transplantation of MSCs
may offer an effective treatment for these patients.
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Introduction
Friedreich ataxia (FRDA) is the commonest autosomal recessive
ataxic condition, affecting around 1 in 50,000 of the population
[1]. FRDA is caused by a homozygous GAA repeat expansion
mutation within intron 1 of the FXN gene (formerly FRDA gene;
[2]). GAA triplet expansion leads to greatly reduced expression of
frataxin, a mitochondrial protein the functions of which include
iron chaperoning in iron-sulphur clusters and heme biosynthesis;
maintenance of anti-oxidant defences; and iron detoxification
[3,4]. The correlation between reduced frataxin levels (longer
GAA expansions) and earlier onset neurological disease implies a
role for frataxin in maintenance and protection of neurons [5].
The precise subsequent mechanisms of cell death and neurode-
generation remain the subject of active research, an increasing
consensus suggests that oxidative damage plays a key role [6,7].
Currently there are no effective treatments to prevent the
progression of FRDA. Major therapeutic strategies in FRDA
include development of agents to protect against oxidative damage
and mitochondrial respiratory chain defects or agents that increase
cellular frataxin expression, since cells lacking frataxin can be
rescued through frataxin expression [8]. With this in mind several
drugs and cytokines have been tested for their ability to increase
frataxin levels in both in vitro and in vivo [9–14]. We hypothesised
that cell replacement therapies could potentially address both
these therapeutic aims, influencing frataxin expression and
offering more widespread cellular protective roles in FRDA. A
large body of research suggests that transplantation of mesenchy-
mal stem cells (MSCs) has therapeutic potential for neurodegen-
erative disorders through a multitude of different mechanisms.
These include replacement of lost cells by differentiation into
functional tissue, modulation of the immune system to prevent
further degeneration, and/or provision of trophic support for the
diseased cellular system [15]. Increasing evidence suggests that the
major mechanistic protective role of MSCs is their capacity to
promote an environment conducive to cellular protection and to
support cell survival through the secretion of a diverse range of
potentially protective factors, including those with anti-oxidant
properties [15–20].
Administration of MSCs is an attractive therapeutic option for
FRDA for several reasons: cells are easily isolated from various
anatomical sources, have a versatile growth and differentiation
potential, and, in addition, the immunosuppressive properties of
MSCs make it probable that allogeneic as well as autologous cell
therapy could be considered. If human MSC transplantation is to
become a viable therapeutic approach for FRDA, a precise
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cells derived from FRDA patients is required.
Here we have performed a series of experiments showing that
human MSCs increase both frataxin gene and protein expression
in fibroblasts derived from patients with FRDA via secretion of
soluble factors. We show a direct link between frataxin expression
in fibroblasts derived from FRDA patients with both decreased
expression of hydrogen peroxide scavenging enzymes and
increased sensitivity to hydrogen peroxide-mediated toxicity.
Furthermore, we have demonstrated that exposure to factors
produced by MSCs increase resistance to hydrogen peroxide
mediated toxicity in these fibroblasts through, at least in part,
restoring the expression of the hydrogen peroxide scavenging
enzymes catalase and glutathione peroxidase 1. These findings
suggest that MSCs may have potential as therapeutic agents for
FRDA and, in time, transplantation of bone marrow-derived
MSCs may offer an effective cellular therapy in these patients.
Materials and Methods
Patients and fibroblast culture
Primary fibroblast cells, derived from skin biopsies of Caucasian
FRDA and control patients, were obtained from the Coreill cell
repositories (Coreill Institute for medical research, New Jersey,
USA). Fibroblasts were grown in DMEM with 10% foetal calf
serum (FCS) (StemCell Technologies, London, UK), and 100 U/
ml penicillin and 100 mg/ml streptomycin (Sigma-Aldrich,
Gillingham, UK). All experiments were on fibroblast cultures
between 8–12 passages.
Transfection of fibroblasts with GFP-tagged FXN
Transfection of fibroblasts was carried out using Amaxa
Nucleofector kits for primary cells (Lonza, Basel, Switzerland).
Prior to nucleofection, confluent fibroblast cultures trypsinized
with trypsin-EDTA. Proteolysis by trypsin was stopped with the
addition of DMEM supplemented with 10% FCS. 3610
5 cells
were then transfected with 2.0 mg GFP-tagged ORF clone of
human frataxin (FXN) (Origene, Maryland, USA) according to
manufactures instructions. The nucleofector programme U-23 was
chosen for high transfection efficiency. Cells were then re-suspend
in 2ml DMEM/10% FCS and cultured within one well of a 6-well
plate. Fluorescence microscopy was used to visualise GFP-tagged
frataxin within FXN transfected fibroblasts. For a mock-treated
control, distilled water was used to replace the vector expression
system.
Establishment of mesenchymal stem cell cultures from
healthy control patients
Bone marrow samples were obtained by an orthopaedic surgeon
at Southmead Hospital, Bristol, UK with informed written consent
and hospital ethic committee approval by the North Bristol NHS
trust research ethics committee. Bone marrow was taken at the
time of total hip replacement surgery from the femoral shaft and
placed into a sterile 50ml tube containing 1000 I.U heparin.
Patients with a history of malignancy, immune disorders or
rheumatoid arthritis were excluded from the study. Femoral shaft
bone marrow donors were healthy apart from osteoarthritis, and
were not receiving drugs known to be associated with myelosup-
pression or bone-marrow failure.
Femoral shaft marrow samples were broken up with a scalpel
and washed with Dulbecco’s Modified Eagles Medium (DMEM)
(Sigma-Aldrich, Gillingham, UK) until remaining material (bone)
looked white at the bottom of the 50 ml tube. All washings were
pipetted into a new 50 ml tube and kept for centrifugation. The
suspension was centrifuged and re-suspended in DMEM and
overlaid onto an equal volume of Lymphoprep (Axis-Shield,
Dundee, UK; density 1.077+/20.001 g/ml) and centrifuged at
600 g for 35 minutes at room temperature to separate the
mononuclear cells (MNC) from neutrophils and red cells. The
MNC layer was harvested and washed twice in DMEM.
MSC culture
Isolated MNCs were centrifuged and re-suspended in MSC
medium consisting of DMEM with 10% foetal calf serum (FCS)
selected for the growth of MSCs (StemCell Technologies, London,
UK), and 100 U/ml penicillin and 100 mg/ml streptomycin
(Sigma-Aldrich, Gillingham, UK). Vented flasks (25 cm
2) contain-
ing 10 ml of MSC medium were seeded with 1610
7 cells for
primary culture. Flasks were incubated at 37uC in a humidified
atmosphere containing 5% CO2 and fed every week with MSC
medium by half medium exchange to remove non-adherent
hematopoietic cells until the adherent fibroblast-like MSCs
reached approximately 70% confluence. On reaching confluence
the adherent cells were re-suspended using 0.25% trypsin (Sigma-
Aldrich, Gillingham, UK) and re-seeded at 2.25610
5 cells per (75
cm
2) flask into first passage. Cultures were then incubated, fed
every week with MSC medium by half medium exchange, and
again trypsinised, a cell count taken and re-seeded at 2.25610
5
cells per flask (75 cm
2).
MSC characterization
MSCs harvested from femoral shaft bone marrow were cultured
and characterised according to previous published reports from
our laboratory [16–18,21,22]. Briefly, MSC cultures were
characterised at third passage using anti-CD105, anti-CD45
(eBioscience, California, USA), anti-CD166 and with anti-CD44
(Serotec, Oxford, UK). MSCs were also differentiated down the
adipogenic, osteoblastic and chondrogenic lineages.
Preparation of mesenchymal stem cell conditioned
medium
Confluent MSCs, at third passage, were washed in DMEM and
cultured for 24hours in minimal base medium (consisting of
Dulbecco’s modified eagles medium supplemented with insulin-
free Sato (containing 100 mg/ml bovine serum albumin, 100 mg/
ml transferrin, 0.06 mg/ml progesterone, 16 mg/ml putrescine,
0.04 mg/ml selenite, 0.04 mg/ml thyroxine, 0.04 mg/ml tri-iodo-
thryonine)[18]. Medium was then removed and stored at 280uC
prior to being used within culture experiments. MSC-conditioned
medium in this study was prepared from at least 6 independent
MSC samples.
Erythropoietin enzyme linked immunosorbent assay
(ELISA)
Mesenchymal stem cell-conditioned medium, derived from
MSCs at varying passages, was analyzed by ELISA using the
Human Erythropoietin ELISA kit (Abnova, Heidelberg, Ger-
many) according to the manufacturer’s instructions. All samples
were analyzed in triplicate.
Real-time Polymerase Chain Reaction (PCR)
Fibroblast cultures were washed in DMEM, trypsinised and
resuspended in PBS. RNA was extracted and cDNA produced
using the Taqman gene expression cells-Ct-kit (Applied Biosys-
tems, Paisley, UK) according to the manufacturer’s instructions.
10
5 cells were added to lysis solution plus DNase (5 minutes)
before the addition of stop solution (2 minutes). All RNA samples
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assay kit (Invitrogen, Paisley, UK) according to manufacturers’
instructions to ensure equal loading of RNA samples. Samples
were stored at 280uC prior to use. To synthesize cDNA, 100 ng of
extracted RNA was added to the reverse transcription buffer and
RT enzyme mix, placed in a thermal cycler, and incubated at
37uC for 1 hour and 95uC for 5 minutes. RT-PCR was performed
using the StepOnePlus Real-Time PCR System (Applied Biosys-
tems, Paisley, UK) with Assay-on-demand Gene Expression
Products for FXN (Taqman MGB probe, FAM dye-labelled,
Applied Biosystems, Paisley, UK) or 18S rRNA (Taqman MGB
probe, VIC dye-labelled, Applied Biosystems, Paisley, UK) using
10 ng of cDNA in a total volume of 20 ml. Reactions were run at
50uC for 2 minutes; 95uC for 10 minutes; and 40 cycles of 95uC
for 15 seconds and 60uC for 1 minute. All samples were analyzed
in triplicate. The relative gene expression (RQ value) of FXN was
calculated using the 2
-DDCt method, and the mean taken for each
group. 18S rRNA was used as the reference ‘housekeeping’ gene.
Immunoblotting
Fibroblasts cultured in a 6-well plate were lysed using Beadlyte
cell signalling universal lysis buffer (Millipore, Watford, UK). The
Qubit Fluorometer and Quant-iT protein assay kit (Invitrogen,
Paisley, UK) was then used to quantify the concentration of total
protein within each cell lysate sample according to manufacturers’
instructions to ensure equal loading of cell lysates. Lysates were
heated to 95uC for five minutes with Laemmli 2x sample buffer
(Invitrogen, Paisley, UK) and run on Tris-HCl 10–20% ready gels
(Bio-Rad, Hemel Hempstead, UK). After transfer to a nitrocel-
lulose membrane (Bio-Rad, Hemel Hempstead, UK) and blocking
in Tris-buffered saline/5% bovine serum albumin, membranes
were incubated overnight in primary antibody at 4uC (in Tris-
buffered saline/5% bovine serum albumin). Antibodies used were
mouse anti-human frataxin (this antibody recognizes a band
migrating at approximately 18 kDa corresponding to the mature
Frataxin protein isoform (aa 56–210)) (1:10000; Millipore, UK),
mouse anti-GAPDH (1:5000; Abcam, Cambridge, UK), rabbit
anti-catalase (1:15000; Abcam, UK), rabbit anti-glutathione
peroxidase 1 (GPX1) (1:5000; Abcam, Cambridge, UK). Immu-
noreactivity was detected using secondary anti-rabbit or anti-
mouse horseradish peroxidase conjugated antibodies (Abcam,
Cambridge, UK) (in Tris-buffered saline/5% bovine serum
albumin) and specific protein expression patterns were visualized
by chemiluminescence using an Amersham ECL Plus Western
Blotting Detection System (GE Healthcare, Little Chalfont, UK).
Densitometic analysis of western blot bands was performed using
ImageJ software (NIH, Maryland, USA).
Frataxin lateral flow dipstick immunoassay
Frataxin levels in fibroblasts-derived from patients with FRDA
were measured using MitoSciences frataxin dipstick (MSF31)
(Mitosciences, Oregon, USA) assays according to manufacturers’
instructions. Briefly, 10 mg of fibroblast protein in 25 mLo f
extraction buffer was mixed with 25 mL blocking buffer and added
to individual wells on a 96-well plate with gold-conjugated
monoclonal antibody at the bottom of each well. Dipsticks were
then inserted into the wells and frataxin within the each sample was
immunocaptured onto designated capture zones on the dipstick.
Densitometic analysis of capture zones on developed dipsticks were
quantified using ImageJ software (NIH, Maryland, USA).
Assessment of H2O2 cytotoxicity
Confluent fibroblast cultures were washed in DMEM, trypsin-
ised and cultured in 96-well plates (10,000 cells per well) in
DMEM/10%FCS. At 24 hours in vitro culture, cells were exposed
to experimental conditions. Medium was removed from all wells
and cells were washed twice in DMEM. Minimal medium and/or
MSC conditioned medium was added to appropriate wells with/
without the addition of 3-AminoTriazole (10mM, Sigma, Gilling-
ham, UK). After a further 24 hours media was removed from all
wells and replaced with minimal medium containing hydrogen
peroxide (600 mM) (Sigma-Aldrich, Gillingham, UK) with/with-
out the addition of 3-AminoTriazole (10mM, Sigma, Gillingham,
UK), catalase from human erythrocytes (10 U/ml, Sigma,
Gillingham, UK), glutathione peroxidase from human erythro-
cytes (10U/ml, Sigma, Gillingham, UK) (An initial dose response
curve to determine the optimal hydrogen peroxide concentration
(600 mM) for the given timed cell survival experiment (data not
shown)). Hydrogen peroxide levels were detectable in the media
for approximately 5 hours, therefore at 6 hours post addition of
hydrogen peroxide, evaluation of fibroblast cell survival was
carried out using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) cell viability assay (96-well plates). For
assessment of hydrogen peroxide cytotoxicity in FXN-transfected
cells, fibroblasts were cultured in DMEM/10%FCS for a total of
48 hours after seeding into wells prior to varying concentrations
hydrogen peroxide for 6 hours as above.
MTT cell viability assay. Briefly, the supernatant was
removed and replaced with HBSS/10%FCS containing 1 mg/
ml MTT (Sigma-Aldrich, Gillingham, UK). Cells were then
incubated for 1 hour at 37uC and subsequently the HBSS/
10%FCS/MTT solution was removed by inverting the plate and
the plate was left to dry. DMSO (Sigma-Aldrich, Gillingham, UK)
was then added to each well and the absorbance of the solution in
each well read in a plate reader at 540 nm. Cell survival was
assessed as a ratio of the amount of formazan production relative
to the respective control. In all cases, control cultures grown
throughout the experimental period in base ‘minimal’ medium
were analyzed and values for the experimental conditions divided
by this value, in order to standardize results between experiments.
Statistical analysis
Statistical comparisons were analyzed using one way ANOVA
with post hoc Bonferroni testing between groups where appropriate.
Paired or unpaired t-tests were used for analysis of normally
distributed data. Values are expressed as the mean +/2 SEM
from at least three independent experiments, taking p,0.05 to
represent statistical significance.
Results
Primary fibroblast cultures derived from skin biopsies of FRDA
and healthy control patients were established (see Table 1).
Fibroblast cultures were morphologically homogenous and
characterized by their spindle-like appearance. To investigate
the effects MSCs have on frataxin expression in fibroblasts derived
from patients with FRDA, patient fibroblasts were exposed to
MSC conditioned medium in vitro and frataxin expression
investigated using western blotting and RT-PCR techniques.
Frataxin expression in human fibroblasts derived from
Friedreich ataxia and healthy control patients
Western blot analysis was used to detect the cellular protein
expression of frataxin, and to verify the characteristic decrease in
frataxin expression within cells derived from patients with FRDA.
Detection using a anti-human frataxin (exon 4) IgG2 antibody
revealed a frataxin protein band at approximately 18kDa for both
healthy control and FRDA cell lysates which corresponds to the
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using ImageJ software calculated that frataxin expression in
fibroblasts derived from patients with FRDA have a significantly
lower in expression of the 18kDa band (p,0.05), with an
approximate 75% decrease in frataxin expression (Figure 1B).
GAPDH expression was used to ensure equal loading of cell
lysates. Frataxin expression by fibroblasts derived from both
healthy control and FRDA patients was also investigated at the
genomic level using RT-PCR. Frataxin mRNA levels differed
significantly between healthy control and FRDA fibroblasts
(p,0.05). Calibration of frataxin mRNA levels with reference to
18S rRNA revealed that fibroblasts derived from patients with
FRDA had also an approximate 75% decrease in frataxin mRNA
expression, under normal culture conditions, when compared to
the control (Figure 1C).
Mesenchymal stem cell conditioned medium
significantly increases Frataxin protein expression
Having shown a significantly reduced frataxin expression in
fibroblasts derived from patients with FRDA, we next wished to
determine the effects of MSC-conditioned medium on frataxin
expression by these cells. Fibroblast cells were cultured for 24 hours
before exposure to experimental conditions. Using immunoblotting
techniques, after 24 hours post exposure to MSC-conditioned
medium, frataxin expression in fibroblasts derived from patients
with FRDA (Figure 2A) and healthy controls (Figure 2B) was
detected. Image analysis using ImageJ software calculated that in
the presence of MSC-conditioned medium frataxin expression in
fibroblasts derived from patients with FRDA was significantly up-
regulated by 2.7-fold after 24 hours exposure when compared to
base minimal media alone (p,0.05) (Figure 2C). This increase in
frataxin expression was evident for up to 72hours post exposure to
MSC-conditioned medium (Figure 2D) (p,0.05). No significant
differences in frataxin expression were evident in fibroblasts derived
from healthy controls after 24 hours exposure to MSC-conditioned
medium when compared to base minimal media alone (p.0.05)
(Figure 2E). GAPDH expression wasused to ensureequal loading of
cell lysates.
A frataxin lateral flow dipstick immunoassay was also used to
investigate the MSC-conditioned medium induced increase in
Table 1. Subject description of Friedreich ataxia patients and age matched healthy controls.
Patient Sex Age GAA expansions Phenotype
FRDA1 F 36 330 and 380 repeats Clinically affected; spinal-cerebral degeneration with cardiomyopathy
FRDA2 F 13 780 and 780 repeats Clinically affected; limb and gait ataxia; scoliosis; proprioceptive sensory loss
FRDA3 M 30 541 and 420 repeats Clinically affected; ataxia; cardiomyopathy; mild peripheral neuropathy
CON1 F 36 n/a normal control
CON2 F 16 n/a normal control
CON3 M 30 n/a normal control
doi:10.1371/journal.pone.0026098.t001
Figure 1. Fibroblasts derived from patients with Friedreich ataxia have low frataxin expression. (A) Immunoblotting of human frataxin
in FRDA and control (CON) fibroblasts. Upper panels correspond to frataxin (FXN); lower panel corresponds to the loading control GAPDH. (B)
Densitometic analysis of frataxin expression of western blot bands. Data are given using arbitrary units of integrated density. (C) The relative frataxin
mRNA expression in control and FRDA fibroblasts . Results are expressed as the mean +/2 (SEM). (*p,0.05, comparing test condition to control; n=3
independent experiments).
doi:10.1371/journal.pone.0026098.g001
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After 24 hours post exposure to MSC-conditioned medium,
frataxin expression in fibroblasts derived from patients with
FRDA was detected (Figure 2F). Image analysis using ImageJ
software calculated that in the presence of MSC-conditioned
medium frataxin expression in fibroblasts derived from patients
with FRDA by was significantly up-regulated by approximately
2.4-fold after 24 hours exposure when compared to base minimal
media alone (p,0.05) (Figure 2G). It was also shown that there
was no frataxin present within the MSC-conditioned medium
sample alone (Figure 2F).
Mesenchymal stem cell conditioned medium
significantly increases Frataxin gene expression
To gain a further understanding into the mechanisms by which
MSC-conditioned medium promotes an increase in frataxin
expression, we investigated frataxin expression at the genomic
level using RT-PCR. At 2, 6 and 24 hours frataxin mRNA levels
from both FRDA patients (Figure 3A) and healthy controls
(Figure 3B) were investigated post exposure to either MSC-
conditioned medium or minimal media alone. Calibration of
frataxin mRNA levels was adjusted with reference to 18S rRNA.
At each time point, no significant differences in frataxin mRNA
expression levels were evident between cells exposed to either
MSC-conditioned medium or minimal media alone (p.0.05).
Analysing the maximal relative frataxin mRNA expression
observed over the 24 hour period, revealed that exposure to
MSC-conditioned medium resulted in an approximate 2-fold
increase in frataxin mRNA expression in fibroblasts derived from
both patients with FRDA (Figure 3C) and healthy controls
(Figure 3D), when compared to exposure to minimal medium
alone (p,0.05).
Figure 2. Mesenchymal stem cell conditioned medium increases frataxin protein expression. Immunoblotting of human frataxin in (A)
FRDA fibroblasts and (B) control fibroblasts after exposure to minimal medium (MIN) or MSC conditioned medium (MSC CM) for 24 hours. Upper
panels correspond to frataxin (FXN); lower panel corresponds to the loading control GAPDH. Western blot densitometic analysis of frataxin expression
in fibroblasts derived from patients with Friedreich ataxia at (C) 24 hours and (D) over a 72 hour period. (E) Western blot densitometic analysis of
frataxin expression in fibroblasts derived from healthy controls. (F) The dipstick immunoassay of human frataxin in FRDA fibroblasts (or MSC CM
alone) after exposure to minimal medium (MIN) or MSC CM for 24 hours. Upper panels correspond to internal control; lower panel corresponds to
human frataxin (FXN). (G) The dipstick immunoassay densitometic analysis of frataxin expression in fibroblasts derived from patients with Friedreich
ataxia. Data are given using arbitrary units of integrated density. Results are expressed as the mean +/2 (SEM). (*p,0.05, comparing test condition to
control; n=3 independent experiments).
doi:10.1371/journal.pone.0026098.g002
Mesenchymal Stem Cells Restore Frataxin Expression
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26098Mesenchymal stem cells increase frataxin expression
through a mechanism independent of erythropoietin
secretion
To determine if MSCs secrete erythropoietin, we performed an
erythropoietin ELISA on four different MSC-conditioned medium
samples. Using this quantitative method, no detectable amount of
erythropoietin was observed in any of the samples tested (data not
shown).
Mesenchymal stem cell conditioned medium
significantly increases both catalase and glutathione
peroxidase 1 expression
We next determined the effects of MSC-conditioned medium
on expression of the hydrogen peroxide scavenging enzymes,
catalase and glutathione peroxidase 1, in fibroblasts derived from
FRDA patients and healthy controls. Fibroblast cells were
cultured for 24 hours before exposure to experimental conditions.
Using immunoblotting techniques and image analysis using
ImageJ software, it was calculated that both catalase and
glutathione peroxidase 1 expression in fibroblasts derived from
patients with FRDA was significantly lower in expression when
compared to the age matched healthy controls (Figure 4A &
Figure 4B) (p,0.05). After 24 hours exposure to MSC-condi-
tioned medium both catalase and glutathione peroxidase 1
expression in fibroblasts derived from patients with FRDA was
significantly up-regulated by approximately 2-fold when com-
pared to base minimal media alone (p,0.05) (Figure 4A &
Figure 4B). No significant differences in catalase and glutathione
peroxidase 1 expression were evident in fibroblasts derived from
healthy controls after 24 hours exposure to MSC-conditioned
medium when compared to base minimal media alone (p.0.05)
(Figure 4C & Figure 4D). GAPDH expression was used to ensure
equal loading of cell lysates.
Increased frataxin expression in FXN transfected FRDA
fibroblasts increases catalase expression. Nucleofection
efficiently delivered GFP-tagged FXN with approximately 76%
(SE +/2 2) of the fibroblasts expressing of GFP 48 hours following
nucleofection(Figure 5A).An increase infrataxinproteinexpression
48 hours post nucleofection was also confirmed using immuno-
blotting techniques. Detection using anti-frataxin antibody revealed
a protein band at approximately 45kDa for transfected cell lysates
which corresponds to the expected weight of the GFP-tagged
frataxin protein. This band was absent from non-DNA transfected
controls (Figure 5B). GAPDH expression was used to ensure equal
loading of cell lysates.
We examined whether there was a direct link between
frataxin expression and the expression of both catalase and
glutathione peroxidase 1 in fibroblasts derived from patients
with FRDA and healthy controls. Using immunoblotting
techniques and image analysis using ImageJ software, it was
calculated that FXN-transfection in fibroblasts-derived from
FRDA patients led to a 4-fold increase in catalase expression
(p,0.05), no significant increase in glutathione peroxidase 1
expression was evident (p.0.05) (Figure 5C & Figure 5D).
FXN-transfection in fibroblasts-derived from healthy controls
resulted in no significant differences in catalase or glutathione
peroxidase 1 expression (p.0.05) (Figure 5E & Figure 5F).
GAPDH expression was used to ensure equal loading of cell
lysates.
Figure 3. Mesenchymal stem cell conditioned medium increases frataxin gene expression. The relative frataxin mRNA expression in (A)
FRDA and (B) control fibroblasts after exposure to minimal medium (MIN) or MSC conditioned medium (MSC CM) for 2, 6 and 24 hours. The mean
maximal relative frataxin mRNA expression in (C) FRDA and (D) control fibroblasts evident throughout the 24 hour exposure to minimal medium
(MIN) or MSC CM. Results are expressed as the mean +/2 (SEM). (*p,0.05, comparing test condition to control; n=3 independent experiments).
doi:10.1371/journal.pone.0026098.g003
Mesenchymal Stem Cells Restore Frataxin Expression
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26098Mesenchymal stem cell conditioned medium or FXN-
transfection increases resistance to hydrogen peroxide
mediated toxicity in fibroblasts derived from Friedreich
ataxia patients
Next we examined the toxicity of hydrogen peroxide to both
fibroblasts derived from healthy controls and patients with FRDA
using a MTT cell viability assay. Initial dose response curves were
used to determine the optimal hydrogen peroxide concentrations.
Cells were either incubated with minimal medium or MSC-
conditioned medium for 24hours prior to insult with/without the
addition of the catalase inhibitor 3-AminoTriazole. Firstly it was
shown that fibroblasts from healthy controls were significantly
more resistant to hydrogen peroxide mediated cellular toxicity
when compared to fibroblasts derived from patients with FRDA
when under normal control conditions (p,0.05) (Figure 6).
Following this it was shown that exposure to MSC-conditioned
medium or FXN-transfection in fibroblasts-derived from patients
with FRDA resulted in a significant increase in cell survival when
compared to cells exposed to minimal medium alone at identical
concentrations of hydrogen peroxide (p,0.05) (Figure 6). The
addition of the catalase inhibitor 3-AminoTriazole abrogated this
increase in cell survival in the cells exposed to MSC-conditioned
medium. The addition of 3-AminoTriazole alone without
hydrogen peroxide exposure, to fibroblasts derived from FRDA
patients, had no significant effect on cell survival. No significant
differences in cell survival after hydrogen peroxide treatment were
evident in fibroblasts derived from healthy controls, post exposure
MSC-conditioned media.
Both the addition of catalase or glutathione peroxidase (derived
from human erythrocytes) at the time of hydrogen peroxide
exposure, led to an increase in FRDA fibroblast cell survival when
compared to hydrogen peroxide alone (p,0.05) (Figure 6).
Discussion
Friedreich ataxia is an incurable, progressive neurodegenerative
condition characterized by multiple symptoms including gait and
limb ataxia, dysarthria and an array of systemic complications
including diabetes mellitus, scoliosis and hypertrophic cardiomy-
opathy which is the principle cause of death [23]. FRDA is
typically caused by a homozygous GAA repeat expansion within
the frataxin gene, resulting in a reduced expression of the frataxin
protein. However, a small proportion of patients are heterozygous
for the expanded allele with the addition of a mutation in the
second allele leading to a premature stop codon [2,24]. The
amount of frataxin gene and protein expression in clinically
symptomatic patients varies from approximately 5–35% of normal
levels.
Heterozygous carriers of the GAA expansion, who are
asymptomatic, have approximately 50% of normal frataxin
expression [25,26]. Thus, clinical interventions that are able to
Figure 4. Mesenchymal stem cell conditioned medium increases both catalase and glutathione peroxidase 1 expression in
fibroblasts-derived from FRDA patients. Immunoblotting of human catalase, glutathione peroxidase 1 (GPX1) and loading control GAPDH in (A)
FRDA/control fibroblasts and (C) control fibroblasts after exposure to minimal medium (MIN) or MSC conditioned medium (MSC CM) for 24 hours.
Western blot densitometic analysis of catalase and GPX1expression in fibroblasts derived from (B) patients with FRDA/controls and (D) control
fibroblasts at 24 hours. Data are given using arbitrary units of integrated density. Results are expressed as the mean +/2 (SEM). (*p,0.05, comparing
test condition to control; n=3 independent experiments).
doi:10.1371/journal.pone.0026098.g004
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therapeutic approaches, as in theory, it may be possible to re-
establish normal function in frataxin defective cells by increasing
frataxin levels above a specific threshold. It has been demonstrated
frataxin knockout cells can be rescued through the insertion of
frataxin using gene therapy techniques [8]. At present there are
several strategies for the treatment of specific symptoms of frataxin
deficiency including agents that protect against oxidative damage
and mitochondrial respiratory chain defects (Idebenone, Pioglita-
zone and Deferiprone) [27–29]. However, several agents that are
able to increase frataxin expression (recombinant erythropoietin
and histone deacetylase enzyme inhibitors (HDACi)) are also being
tested [9–14].
In this study, we have performed a series of experiments
investigating the effects human MSCs have on both frataxin gene
and protein expression in fibroblasts derived from patients with
FRDA and healthy controls. We show that human MSCs, via the
secretion of soluble factors, are able to increase frataxin mRNA
expression promoting a prolonged increase in frataxin protein
expression in fibroblasts derived from patients with FRDA.
Increases in frataxin mRNA expression over a 24 hour exposure
to MSC-condition medium were also evident within our healthy
control group although no significant differences in frataxin
protein expression were observed. This may however be associated
with the relatively low sample numbers in this group. It is believed
that GAA repeats in FRDA patients block transcription via several
proposed mechanisms including impeding the progress of RNA
polymerase [30] and the induction of an inaccessible heterochro-
matin structure [31]. The different GAA expansion lengths in the
FRDA patients could therefore explain the large variation in the
Figure 5. Enhanced frataxin expression in FXN-transfected FRDA fibroblasts increases catalase expression. (A) FRDA fibroblast culture
transfected with a GFP-tagged FXN gene. (B) Immunoblotting of human frataxin in GFP-tagged frataxin transfected (right) and untransfected (left)
FRDA fibroblasts. Upper panels correspond to frataxin; lower panel corresponds to the loading control GAPDH. Immunoblotting of human catalase,
glutathione peroxidase 1 (GPX1) and loading control GAPDH in (C) FRDA fibroblasts and (E) control fibroblasts after transfection with the GFP-tagged
FXN gene. Western blot densitometic analysis of catalase and GPX1expression in fibroblasts derived from (D) patients with FRDA and (F) control
fibroblasts at 24 hours. Data are given using arbitrary units of integrated density. Results are expressed as the mean +/2 (SEM). (*p,0.05, comparing
test condition to control; n=3 independent experiments).
doi:10.1371/journal.pone.0026098.g005
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conditioned medium. Indeed, if any increase in frataxin mRNA is
observed a prolonged increase of mature frataxin protein would be
expected to follow due to the half-life of mature frataxin being
approximately two days [32]. The maximal frataxin mRNA
expression of each sample post exposure to MSC-conditioned
medium resulted in a 2-mean fold increase in frataxin mRNA
expression in fibroblasts derived from patients with FRDA. This
correlated well with the prolonged increase in frataxin protein
expression observed in cells derived from FRDA patients. Similar
studies using HDAC inhibitors and erythropoietin have reported
increases in frataxin protein expression in primary cells derived
from patients with FRDA in vitro [9,10,13,14], with studies
showing increases in frataxin protein with and without corre-
sponding increases in frataxin mRNA [9,13]. Increases in frataxin
protein expression have also been confirmed using recombinant
erythropoietin in clinical studies in FRDA patients [11,33,34]. To
determine if MSCs secrete erythropoietin, thus a possible
mechanism by which they promote an increase in frataxin
expression, we analyzed several different MSC-conditioned
medium samples using an erythropoietin ELISA. Using this
method, no detectable amount of erythropoietin was present,
therefore indicating MSCs increase frataxin expression through a
mechanism independent of erythropoietin secretion.
Oxidative damage and inhibition of mitochondrial function
may be key determinants of cellular damage and the pathogenesis
of FRDA. Cells deficient of frataxin are shown to have a greater
sensitivity to oxidative stress [35–38], and are also shown to have
an impaired ability to recruit antioxidant defences against an
endogenous oxidative stress [39]. Increased sensitivity of FRDA
fibroblasts to hydrogen peroxide has been previously reported
[40–43]. As hydrogen peroxide reacts slowly with biological
molecules, hydrogen peroxide mediated cellular toxicity mainly
occurs through labile (chelatable) iron ions, which catalyze the
formation of the hydroxyl radical from hydrogen peroxide [40].
Reduction in cellular frataxin in patients with FRDA is associated
with free iron accumulation within the mitochondria, leading to
increased levels of Fenton-reactive iron ions, and thus increasing
cellular sensitivity to hydrogen peroxide mediated oxidative stress.
Some studies suggest links between frataxin expression, oxidative
stress and the impairment of the anti-oxidant enzymes glutathione
peroxidase and catalase [44–48]. We therefore investigated the
effect of human MSCs or FXN-transfection has on the expression
of these intracellular hydrogen peroxide scavenging enzymes.
Firstly it was shown that there was a deficiency in both catalase
and glutathione peroxidase 1 in patients with FRDA when
compared to healthy controls. Furthermore, FXN-transfection or
human MSCs, via the secretion of soluble factors, are able to
increase catalase and/or glutathione peroxidase 1 protein levels in
fibroblasts derived from patients with FRDA. Exposure to MSC-
conditioned media or FXN-transfection did not result in any
significant increases in enzymes expression in healthy control cells.
These results are therapeutically interesting as administration of
enzymes that scavenge hydrogen peroxide, such as catalase, or the
addition of hydrogen peroxide scavenging enzyme mimetics may
normalize the antioxidant activity and suppress the deleterious
phenotypes associated with frataxin deficiency [38,49,50].
We have confirmed observations made by others demonstrating
that fibroblasts from healthy controls were more resistant to
hydrogen peroxide-mediated oxidative stress compared to FRDA
fibroblasts [35–38]. We have shown that prior incubation of FRDA
fibroblasts with MSC-conditioned medium before hydrogen
peroxide exposure results in an increase in resistance to hydrogen
peroxide-mediated cell toxicity. MSCs are known to secrete a vast
plethora of effector cytokines and growth factors known for their
cellular protective properties, and within our laboratories we have
previously demonstrated that MSCs protect cells against toxic
insults via modulation of signalling cascades such as the PI3kinase/
Akt and p38 MAPkinase pathways [17,18]. Pre-exposure to MSC-
conditioned media on the other hand did not result in rescue of
fibroblasts from healthy controls. Increasing frataxin expression in
FRDA fibroblasts using FXN-transfection, in addition to increasing
catalase expression, also rescues cells from hydrogen peroxide
exposure. Both the addition of exogenous catalase or glutathione
peroxidase rescue FRDA fibroblasts against hydrogen peroxide
toxicity. Furthermore, the presence of a catalase inhibitor abrogates
the increase in FRDA fibroblast survival, caused by exposure to
MSC-conditioned medium during insult by hydrogen peroxide.
Overall these results suggest a direct link between frataxin, levels of
catalase expression and sensitivity to hydrogen peroxide mediated
toxicity. We hypothesize therefore that an increase in frataxin,
catalase and/or glutathione peroxidase 1 levels in fibroblasts
derived from patients with FRDA after exposure to MSC-
conditioned medium results in, at least in part, this rescue effect.
Therapeutically, MSCs may be able to rescue normal function and
normalize antioxidant activity in frataxin defective cells by
increasing frataxin levels above a specific threshold at which point
patients’ with FRDA become asymptomatic.
Figure 6. Mesenchymal stem cell conditioned medium or FXN-
transfection increases resistance to hydrogen peroxide medi-
ated toxicity in fibroblasts derived from FRDA patients. The
effect of hydrogen peroxide (600 mM) on FRDA and control fibroblast
cell survival in vitro post exposure to minimal medium (MIN) or MSC-
conditioned medium (MSC CM) for 24hours, with/without the addition
of the catalase inhibitor 3-AminoTriazole (CATIN), catalase (CAT) and
glutathione peroxidase (GPX1). FXN indicates fibroblasts have been
transfected with the GFP-tagged FXN gene. Cell survival was assesed
using the MTT cell viability assay (MTT). Cell survival is expressed as a
percentage of cell survival compared to cells grown in minimal medium
alone. Results are expressed as the mean +/2 (SEM). (*p,0.05,
comparing test condition to control; n=3 independent experiments).
doi:10.1371/journal.pone.0026098.g006
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progression of FRDA. Data in this study demonstrates for the first
time that MSCs secrete factors that increase cellular frataxin levels
in frataxin-deficient fibroblasts and protect those cells from
oxidative damage. Increasing evidence suggests a major protective
role of MSCs is their capacity to secrete a diverse range of
potentially trophic, paracrine and protective factors, in addition to
anti-oxidant actions, thereby promoting an environment condu-
cive to cellular protection and support diseased cell survival [15–
20,51,52]. Transplantation of MSCs has the potential to be an
effective treatment for FRDA through a multitude of different
mechanisms. A number of studies have shown that intravenous
delivery of bone marrow derived cells, in humans and experi-
mental animals, results in significant numbers of cells entering the
CNS parenchyma, including the cerebellum [21,53–55]. Further
to this, following transplantation of MSCs for both neurological
and myocardial injury, significant improvements in many clinical
parameters tested have been demonstrated [21,56–58]. Adminis-
tration of MSCs is an attractive therapeutic option in FRDA:
MSCs are easily isolated from various anatomical sources, have a
versatile growth and differentiation potential, and, by virtue of
their immunosuppressive properties, have potential as either an
allogeneic or autologous cell therapy. Furthermore the safety of
injecting MSCs intravenously in humans has been extensively
confirmed in a number of diseases [59]. Rapid clinical translation
of our experimental studies could therefore be justified. Overall
our findings demonstrate, for the first time, a potential role for cell-
based therapies in FRDA and, in time, transplantation of bone
marrow-derived MSCs may offer an effective treatment in these
patients.
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